CU20190092A7 - Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas - Google Patents
Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosasInfo
- Publication number
- CU20190092A7 CU20190092A7 CU2019000092A CU20190092A CU20190092A7 CU 20190092 A7 CU20190092 A7 CU 20190092A7 CU 2019000092 A CU2019000092 A CU 2019000092A CU 20190092 A CU20190092 A CU 20190092A CU 20190092 A7 CU20190092 A7 CU 20190092A7
- Authority
- CU
- Cuba
- Prior art keywords
- antimitoscinas
- stem cells
- cancer stem
- specific inhibitors
- mitochondrial biogenesis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70585—CD44
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
<p>La presente invención se refiere a un compuesto de antimitoscina que comprende un antibiótico que tiene propiedades antimitocondriales intrínseca modificado químicamente con una señal que fija como objetivo para dirigir el compuesto a las mitocondrias y aumentar las propiedades anticancerosas.</p>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762508702P | 2017-05-19 | 2017-05-19 | |
PCT/US2018/033466 WO2018213751A1 (en) | 2017-05-19 | 2018-05-18 | Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
Publications (1)
Publication Number | Publication Date |
---|---|
CU20190092A7 true CU20190092A7 (es) | 2020-10-20 |
Family
ID=64274780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2019000092A CU20190092A7 (es) | 2017-05-19 | 2018-05-18 | Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas |
Country Status (20)
Country | Link |
---|---|
US (2) | US11160821B2 (es) |
EP (1) | EP3624840A4 (es) |
JP (1) | JP6938682B2 (es) |
KR (1) | KR20200010343A (es) |
CN (1) | CN111315400A (es) |
AU (1) | AU2018270129B2 (es) |
BR (1) | BR112019024264A2 (es) |
CA (1) | CA3063717C (es) |
CL (1) | CL2019003283A1 (es) |
CO (1) | CO2019012888A2 (es) |
CR (1) | CR20190524A (es) |
CU (1) | CU20190092A7 (es) |
DO (1) | DOP2019000294A (es) |
EC (1) | ECSP19082194A (es) |
IL (1) | IL270598B (es) |
MX (1) | MX2019013735A (es) |
PE (1) | PE20200605A1 (es) |
RU (1) | RU2019142102A (es) |
WO (1) | WO2018213751A1 (es) |
ZA (3) | ZA201907654B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3060510A1 (en) | 2017-04-21 | 2018-10-25 | Lunella Biotech, Inc. | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
WO2018195446A1 (en) | 2017-04-21 | 2018-10-25 | Lisanti Michael P | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
CA3063450A1 (en) | 2017-05-19 | 2018-11-22 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
RU2019142102A (ru) | 2017-05-19 | 2021-06-21 | Лунелла Байотек, Инк. | Антимитосцины: направленные ингибиторы митохондриального биогенеза для эрадикации злокачественных стволовых клеток |
BR112019026097A2 (pt) | 2017-06-26 | 2020-07-07 | Lunella Biotech, Inc. | mitoketoscins: terapêuticos à base de mitocôndrias com direcionamento no metabolismo da cetona em células cancerígenas |
WO2019075226A1 (en) | 2017-10-11 | 2019-04-18 | Lunella Biotech, Inc. | ANTI-MITOCHONDRIAL INHIBITORS FOR ONCOGENIC RAS AND MYC |
US11497759B2 (en) * | 2017-12-01 | 2022-11-15 | Lunella Biotech, Inc. | Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
JP7538119B2 (ja) | 2018-10-02 | 2024-08-21 | ルネラ・バイオテック・インコーポレーテッド | 老化細胞死誘導薬としてのアジスロマイシンおよびロキシスロマイシン誘導体 |
MX2021007345A (es) * | 2018-12-17 | 2021-07-15 | Lunella Biotech Inc | Terapias de combinacion triple para fijar como objetivo mitocondrias y aniquilar celulas madre cancerosas. |
WO2020131704A1 (en) * | 2018-12-17 | 2020-06-25 | Lunella Biotech, Inc. | Triple combination therapies for anti-aging |
WO2020242857A1 (en) | 2019-05-24 | 2020-12-03 | Lunella Biotech, Inc. | Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer |
BR112021026324A2 (pt) * | 2019-06-26 | 2022-04-12 | Lunella Biotech Inc | Compostos de carbocianina para direcionamento de mitocôndrias e erradicação de células-tronco cancerosas |
EP4048246B1 (en) * | 2019-10-24 | 2024-07-10 | The Medical College of Wisconsin, Inc. | Mitochondria-targeted atovaquone: a more potent and more effective antitumor, antimicrobial, and antimalarial drug |
AU2021271315A1 (en) * | 2020-05-13 | 2022-12-01 | Lunella Biotech, Inc. | Myristoyl derivatives of 9-amino-doxycycline for targeting cancer stem cells and preventing metastasis |
JP2023547108A (ja) * | 2020-10-22 | 2023-11-09 | ルネラ・バイオテック・インコーポレーテッド | γサブユニットを標的とするミトコンドリアATP阻害剤は転移を予防する |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2862921A (en) * | 1953-08-13 | 1958-12-02 | Upjohn Co | Erythromycin esters |
US3517067A (en) | 1964-02-11 | 1970-06-23 | Eastman Kodak Co | Syntheses of quaternary phosphonium salts |
DK149776C (da) | 1984-01-06 | 1987-04-21 | Orion Yhtymae Oy | Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen |
EP0310361A3 (en) | 1987-09-30 | 1989-05-24 | Beckman Instruments, Inc. | Tridentate conjugate and method of use thereof |
SI9011409A (en) | 1990-07-18 | 1995-10-31 | Pliva Pharm & Chem Works | O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them |
EP0656422B1 (en) | 1993-11-05 | 2000-04-26 | Amersham Pharmacia Biotech UK Limited | Chloramphenicol acetyl transferase (CAT) assay |
WO1995015770A1 (en) | 1993-12-09 | 1995-06-15 | Neorx Corporation | Pretargeting methods and compounds |
US5441939A (en) | 1994-03-04 | 1995-08-15 | Pfizer Inc. | 3"-desmethoxy derivatives of erythromycin and azithromycin |
US5795871A (en) | 1994-04-26 | 1998-08-18 | Nobuhiro Narita | Pharmaceutical composition for treatment of non-small cell lung cancer |
EP0823893A1 (en) | 1995-05-03 | 1998-02-18 | Pfizer Inc. | Novel tetracycline derivatives |
US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
US5837696A (en) | 1997-01-15 | 1998-11-17 | The Research Foundation Of State University Of New York | Method of inhibiting cancer growth |
JP4590523B2 (ja) | 1997-11-25 | 2010-12-01 | アンティポディーン ファーマシューティカルズ インコーポレイテッド | ミトコンドリアを標的とする抗酸化剤 |
DK0941998T3 (da) | 1998-03-03 | 2004-09-20 | Pfizer Prod Inc | 3,6-ketalmakrolidantibiotika |
AUPP437698A0 (en) | 1998-06-30 | 1998-07-23 | Baumgart, Karl | Methods for treatment of coronary, carotid and other vascular disease |
US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
MXPA04005611A (es) | 2001-12-11 | 2005-04-19 | Cellgate Inc | Reactivos y conjugados de transporte de guanidinio. |
US7485298B2 (en) | 2002-05-23 | 2009-02-03 | Michael Powell | Diagnosis and treatment of human dormancy-related sequellae |
RU2223103C1 (ru) * | 2002-07-17 | 2004-02-10 | Открытое акционерное общество "Биосинтез" | Фармацевтическая композиция, обладающая антибактериальным действием |
TWI492750B (zh) | 2003-01-27 | 2015-07-21 | 安德賽特公司 | 維生素-受體結合性藥物輸送共軛物、醫藥組合物、用途及製備方法 |
WO2005062851A2 (en) | 2003-12-22 | 2005-07-14 | Pappolla Miguel A | Indole-3-propionamide and derivatives thereof |
JP2005200419A (ja) | 2004-01-16 | 2005-07-28 | National Health Research Inst | 癌治療法 |
WO2005082376A1 (en) | 2004-02-26 | 2005-09-09 | Advanced Ocular Systems Limited | Tetracycline derivatives for the treatment of ocular pathologies |
US20060083727A1 (en) | 2004-07-15 | 2006-04-20 | Nanobac Pharmaceuticals, Inc. | Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation |
TW200616604A (en) | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
US7989600B2 (en) | 2005-01-14 | 2011-08-02 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Macrolide compounds containing biotin and photo-affinity group for macrolide target identification |
CN1706391A (zh) * | 2005-05-09 | 2005-12-14 | 史同瑞 | 土霉素混悬乳剂 |
NZ587586A (en) | 2005-07-18 | 2012-04-27 | Bipar Sciences Inc | Treatment of cancer |
CN1837229A (zh) * | 2005-08-05 | 2006-09-27 | 济南思创生物技术有限公司 | 克拉霉素衍生物及其制备方法和药物应用 |
DE102005039579B4 (de) | 2005-08-19 | 2022-06-30 | Magforce Ag | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
CN1837225A (zh) | 2005-08-23 | 2006-09-27 | 济南思创生物技术有限公司 | 阿奇霉素衍生物及其制法和药物应用 |
EP2094268A2 (en) | 2006-05-26 | 2009-09-02 | Bayer HealthCare, LLC | Drug combinations with substituted diaryl ureas for the treatment of cancer |
JP2009539769A (ja) | 2006-06-02 | 2009-11-19 | アリアド ジーン セラピューティクス インコーポレイテッド | カペシタビン併用療法 |
EP2079484A4 (en) | 2006-09-07 | 2010-03-17 | Stemline Therapeutics Inc | MONITORING OF CANCER STEM CELLS |
AU2007314366A1 (en) | 2006-10-30 | 2008-05-08 | Southern Research Institute | Targeting NBS1-ATM interaction to sensitize cancer cells to radiotherapy and chemotherapy |
PL2117520T3 (pl) | 2006-12-14 | 2019-03-29 | Abraxis Bioscience, Llc | Terapia raka piersi w oparciu o status występowania receptora hormonalnego przy użyciu nanocząstek zawierających taksan |
US8075902B2 (en) | 2007-01-03 | 2011-12-13 | Michael Powell | Diagnosis and treatment of cancer related to human dormancy |
DE102007025423A1 (de) | 2007-05-30 | 2008-12-04 | Friedrich-Schiller-Universität Jena | Triphenylphosphonium-Derivate zum gezielten Transport und Freisetzen von Substanzen in Mitochondrien sowie Verfahren zu deren Verwendung |
WO2008150845A1 (en) | 2007-05-31 | 2008-12-11 | Vanderbilt University | Screening for wnt pathway modulators and pyrvinium for the treatment of cance |
WO2009015214A2 (en) | 2007-07-24 | 2009-01-29 | Wayne State University | Nanoparticles for imaging and treating chlamydial infection |
JP2011501731A (ja) * | 2007-09-10 | 2011-01-13 | ユニバーシティ オブ マサチューセッツ | ミトコンドリア標的化抗腫瘍剤 |
WO2009038656A1 (en) | 2007-09-17 | 2009-03-26 | Kosta Steliou | Mitochondria-targeting antioxidant therapeutics |
WO2009045443A2 (en) | 2007-10-02 | 2009-04-09 | The University Of Rochester | Methods and compositions related to synergistic responses to oncogenic mutations |
EP2419095A4 (en) | 2009-04-17 | 2012-12-05 | Colby Pharmaceutical Company | PHARMACEUTICALLY ACTIVE COMPOSITIONS COMPRISING OXIDATIVE STRESS MODULATORS (OSM), NOVEL CHEMICAL ENTITIES, COMPOSITIONS AND USES |
GB0912584D0 (en) | 2009-07-20 | 2009-08-26 | Ucl Business Plc | Cyclosporin conjugates |
SG178556A1 (en) | 2009-08-25 | 2012-03-29 | Harvard College | Use of metformin in cancer treatment and prevention |
ES2388478T3 (es) * | 2009-12-02 | 2012-10-15 | Bettina Heil | Supositorio para la administración rectal, vaginal o uretral que contiene un probiótico, un antibiótico y un ácido graso insaturado no esterificado |
HUE053793T2 (hu) | 2009-12-04 | 2021-07-28 | Oncoc4 Inc | Hipoxia indukálta faktor gátlók alkalmazásai |
JP2013521314A (ja) | 2010-03-10 | 2013-06-10 | ユニバーシティー ヘルス ネットワーク | 癌の処置のためのチゲサイクリンの使用 |
CN101810570B (zh) * | 2010-04-16 | 2012-06-20 | 成都师创生物医药科技有限公司 | 蒽环类抗肿瘤抗生素脂肪酸复合物脂质纳米粒制剂及其制备方法 |
US20110268722A1 (en) | 2010-04-22 | 2011-11-03 | Siegelin Markus D | Combination therapies with mitochondrial-targeted anti-tumor agents |
US20120141467A1 (en) | 2010-12-03 | 2012-06-07 | Schneider Daniel J | Ascorbic acid to treat chronic obstructive lung diseases and non-Hodgkin's lymphoma |
US10513539B2 (en) | 2011-02-10 | 2019-12-24 | Ruprecht-Karls-Universitat Heidelberg | Hydrophobic modified peptides and their use for liver specific targeting |
CA2840215A1 (en) | 2011-06-22 | 2012-12-27 | Abhijit S. BAPAT | Conjugate-based antifungal and antibacterial prodrugs |
US10441577B2 (en) | 2011-07-08 | 2019-10-15 | Helmholtz Zentrum Fuer Infektionsforschung | Medicament for treatment of liver cancer |
CN102911226B (zh) * | 2011-08-03 | 2015-11-25 | 胡梨芳 | 硬脂酸红霉素类化合物物实体及其用途 |
WO2013019975A1 (en) | 2011-08-03 | 2013-02-07 | University Of Iowa Research Foundation | Compositions and methods of treating cancer |
WO2013024467A2 (en) | 2011-08-18 | 2013-02-21 | Ecole Polytechnique Federale De Lausanne (Epfl) | Mitochondrial ribosomal proteins as aging regulators |
US9775855B2 (en) | 2011-09-14 | 2017-10-03 | Thomas J. Lewis | Compositions comprising macrolide and tetracycline and their uses |
US9394233B2 (en) | 2012-03-01 | 2016-07-19 | Cincinnati Children's Hospital Medical Center | ROS-activated compounds as selective anti-cancer therapeutics |
WO2014036037A1 (en) | 2012-08-28 | 2014-03-06 | Annam Biosciences, Llc | N-boc-dendrimers and their conjugates |
US20150224169A1 (en) | 2012-09-06 | 2015-08-13 | Mcmaster University | Compounds and methods for selectively targeting cancer stem cells |
US20140106004A1 (en) | 2012-10-12 | 2014-04-17 | Bing Lou Wong | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence |
US9636329B2 (en) | 2012-11-06 | 2017-05-02 | Northwestern University | Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors |
US9622982B2 (en) | 2013-01-14 | 2017-04-18 | Health Clinics Limited | Cancer drug and uses |
US9937161B2 (en) | 2013-03-06 | 2018-04-10 | The General Hospital Corporation | Combinatorial compositions and methods for treatment of melanoma |
EP2989110B1 (en) | 2013-04-24 | 2018-08-08 | Smart Brain s.r.o. | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level |
WO2015002996A1 (en) | 2013-07-01 | 2015-01-08 | University Of Georgia Research Foundation, Inc. | Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy |
US10130590B2 (en) | 2013-10-01 | 2018-11-20 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer with atovaquone-related compounds |
CN103536530A (zh) * | 2013-10-30 | 2014-01-29 | 王玉万 | 盐酸多西环素长效注射剂及制备方法 |
US20150231069A1 (en) | 2014-02-20 | 2015-08-20 | Pankaj Modi | Oral formulations of chemotherapeutic agents |
US10398663B2 (en) | 2014-03-14 | 2019-09-03 | University Of Georgia Research Foundation, Inc. | Mitochondrial delivery of 3-bromopyruvate |
US20170224730A1 (en) | 2014-06-10 | 2017-08-10 | Institute For Myeloma & Bone Cancer Research | Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid |
GB201414806D0 (en) | 2014-08-20 | 2014-10-01 | Ucl Business Plc | Cyclosporin conjugates |
EP3206674B1 (en) | 2014-10-17 | 2020-03-18 | Targeted Therapies Research and Consulting Centre | Multi-ingredient pharmaceutical composition for use in cancer therapy |
CN104352566A (zh) * | 2014-10-21 | 2015-02-18 | 河南牧翔动物药业有限公司 | 一种水包油型复方金霉素纳米乳 |
JP6439931B2 (ja) | 2015-02-26 | 2018-12-19 | 大日本印刷株式会社 | 吸着搬送装置および吸着搬送方法 |
CA2997671A1 (en) | 2015-10-06 | 2017-04-13 | Redhill Biopharma Ltd. | Combination therapies for treating cancer |
CN105884633B (zh) * | 2016-05-07 | 2017-12-26 | 浙江大学 | 一种四环素硬脂酸嫁接物及其制备和应用 |
AU2016419048B2 (en) | 2016-08-11 | 2024-02-15 | The Council Of The Queensland Institute Of Medical Research | Immune-modulating compounds |
CN106511317A (zh) * | 2016-12-13 | 2017-03-22 | 浙江中同科技有限公司 | 一种掩味克拉霉素颗粒的制备方法 |
WO2018136598A1 (en) | 2017-01-18 | 2018-07-26 | Evelo Biosciences, Inc. | Methods of treating cancer |
US20200121739A1 (en) | 2017-01-18 | 2020-04-23 | Evelo Biosciences, Inc. | Bacteria for treating cancer |
WO2018195446A1 (en) | 2017-04-21 | 2018-10-25 | Lisanti Michael P | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
CA3060510A1 (en) | 2017-04-21 | 2018-10-25 | Lunella Biotech, Inc. | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
WO2018202910A1 (en) | 2017-05-05 | 2018-11-08 | Fondazione Istituto Italiano Di Tecnologia | Combination of antibiotic and bcl-2 inhibitor and uses thereof |
RU2019142102A (ru) | 2017-05-19 | 2021-06-21 | Лунелла Байотек, Инк. | Антимитосцины: направленные ингибиторы митохондриального биогенеза для эрадикации злокачественных стволовых клеток |
CA3063450A1 (en) | 2017-05-19 | 2018-11-22 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
WO2018218242A1 (en) | 2017-05-26 | 2018-11-29 | Epicentrx, Inc. | Methods and compositions for combination therapy |
MX2020005311A (es) | 2017-11-24 | 2020-08-17 | Lunella Biotech Inc | Compuestos de derivados de trifenilfosfonio para erradicar celulas madre cancerosas. |
WO2019126179A1 (en) | 2017-12-20 | 2019-06-27 | Lunella Biotech, Inc. | Targeting mitochondrial fission through mdivi-1 derivatives |
-
2018
- 2018-05-18 RU RU2019142102A patent/RU2019142102A/ru not_active Application Discontinuation
- 2018-05-18 AU AU2018270129A patent/AU2018270129B2/en active Active
- 2018-05-18 MX MX2019013735A patent/MX2019013735A/es unknown
- 2018-05-18 EP EP18803298.1A patent/EP3624840A4/en not_active Withdrawn
- 2018-05-18 BR BR112019024264-3A patent/BR112019024264A2/pt unknown
- 2018-05-18 US US16/614,623 patent/US11160821B2/en active Active
- 2018-05-18 CR CR20190524A patent/CR20190524A/es unknown
- 2018-05-18 CN CN201880046651.0A patent/CN111315400A/zh active Pending
- 2018-05-18 PE PE2019002430A patent/PE20200605A1/es unknown
- 2018-05-18 JP JP2019563871A patent/JP6938682B2/ja active Active
- 2018-05-18 CU CU2019000092A patent/CU20190092A7/es unknown
- 2018-05-18 CA CA3063717A patent/CA3063717C/en active Active
- 2018-05-18 WO PCT/US2018/033466 patent/WO2018213751A1/en active Search and Examination
- 2018-05-18 KR KR1020197037193A patent/KR20200010343A/ko not_active Application Discontinuation
-
2019
- 2019-11-12 IL IL270598A patent/IL270598B/en unknown
- 2019-11-15 CL CL2019003283A patent/CL2019003283A1/es unknown
- 2019-11-18 CO CONC2019/0012888A patent/CO2019012888A2/es unknown
- 2019-11-19 EC ECSENADI201982194A patent/ECSP19082194A/es unknown
- 2019-11-19 DO DO2019000294A patent/DOP2019000294A/es unknown
- 2019-11-19 ZA ZA2019/07654A patent/ZA201907654B/en unknown
-
2021
- 2021-04-16 ZA ZA2021/02509A patent/ZA202102509B/en unknown
- 2021-10-01 US US17/491,672 patent/US11865130B2/en active Active
-
2022
- 2022-03-07 ZA ZA2022/02712A patent/ZA202202712B/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2019013735A (es) | 2020-01-15 |
PE20200605A1 (es) | 2020-03-10 |
RU2019142102A3 (es) | 2021-06-21 |
CO2019012888A2 (es) | 2020-05-15 |
WO2018213751A1 (en) | 2018-11-22 |
CR20190524A (es) | 2020-01-10 |
NZ760422A (en) | 2023-11-24 |
CN111315400A (zh) | 2020-06-19 |
AU2018270129A1 (en) | 2020-01-16 |
ZA202202712B (en) | 2023-11-29 |
RU2019142102A (ru) | 2021-06-21 |
ZA201907654B (en) | 2022-07-27 |
US20220072020A1 (en) | 2022-03-10 |
EP3624840A1 (en) | 2020-03-25 |
CL2019003283A1 (es) | 2020-05-04 |
ZA202102509B (en) | 2023-03-29 |
IL270598B (en) | 2022-04-01 |
US11160821B2 (en) | 2021-11-02 |
JP6938682B2 (ja) | 2021-09-22 |
ECSP19082194A (es) | 2019-11-30 |
US11865130B2 (en) | 2024-01-09 |
AU2018270129B2 (en) | 2021-01-07 |
BR112019024264A2 (pt) | 2020-06-02 |
EP3624840A4 (en) | 2021-03-10 |
US20200179424A1 (en) | 2020-06-11 |
DOP2019000294A (es) | 2020-02-16 |
KR20200010343A (ko) | 2020-01-30 |
JP2020527127A (ja) | 2020-09-03 |
CA3063717A1 (en) | 2018-11-22 |
CA3063717C (en) | 2021-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20190092A7 (es) | Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas | |
ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
BR112015028171A8 (pt) | Inibidores de acc e seu uso | |
CL2016000925A1 (es) | Inhibidores de bromodominio | |
CU20160006A7 (es) | Derivados de piperidinil-indol como inhibidores de factor de complemento b | |
DOP2016000085A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
CL2015002658A1 (es) | Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio | |
BR112018006811A2 (pt) | compostos terapêuticos e métodos | |
CL2015002858A1 (es) | Un cigarrillo simulado. | |
BR112017011440A2 (pt) | uma composição antimicrobiana | |
EP3717015A4 (en) | REPURPOSCINS: TARGET MITOCHONDRIAL BIOGENESIS INHIBITORS TO ERADICATE CARCINOUS STEM CELLS | |
BR112016006874A2 (pt) | uso de picolinamidas macrocíclicas como fungicidas | |
CR20130354S (es) | Banda de rodadura de neumático | |
BR112016006366A2 (pt) | uso de picolinamidas macrocíclicas como fungicidas | |
CL2016000009A1 (es) | Tratamiento de rosacea papulopustular con ivermectina. | |
BR112017022281A2 (pt) | métodos para tratar câncer | |
GT201500247A (es) | Imidazopiridazinas sustituidas | |
CL2015002180A1 (es) | Terapia de combinación para el tratamiento de neumonía nosocomial | |
CL2018003026A1 (es) | Loci genéticos asociados con una mayor fertilidad en el maíz (divisional de la solicitud n° 2071-2016). | |
DOP2019000230A (es) | MITORRIBOSCINAS: COMPUESTOS TERAPÉUTICOS BASADOS EN MITOCONDRIAS QUE FIJAN COMO OBJETIVO CÉLULAS CANCEROSAS, BACTERIAS y LEVADURAS PATÓGENAS | |
BR112015022162A2 (pt) | sonda fluorescente de zinco | |
ECSP18018793A (es) | Compuestos útiles para inhibir ror-gamma-t | |
UY37560A (es) | Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta | |
CO2017001626A2 (es) | Anticuerpo anti-orai1 | |
CO2021009008A2 (es) | Terapias de combinación triple para anti-envejecimiento |